Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria

NCT01992900 is registered in ClinicalTrials.gov with sigma-tau i.f.r. S.p.A. as lead sponsor.

NCT NCT01992900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01992900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria
Lead sponsor
sigma-tau i.f.r. S.p.A.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
January 31, 2016
Enrollment
300 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

malaria,falciparum